Textbook of Personalized Medicine - Second Edition [2015]

225 generate a dose-response curve for each chemotherapeutic agent tested on a given patient specimen. Features of each dose-res ...

226 on patients with breast cancer and lung cancer. This technology will allow physicians to tailor the treatment and prognosis ...

227 whole genomes and ultra-deep sequencing of target genes. The method is not only very sensitive, but it is also quantitative ...

228 (TNF)-related apoptosis-inducing ligand) it is common for some cells in a clonal population to die while others survive − a ...

229 ineffective treatment. Receiving ineffective therapy for longer than needed also delays the start of second-line therapies t ...

230 Baseline value of biomarker CYFRA 21-1. In advanced stage NSCLC, the initial level of serum CYFRA appears to provide more p ...

231 steps catalyzed by endogenous nucleoside kinases. Deoxycytidine kinase (DCK) controls the rate-limiting step in the activati ...

232 Molecular Diagnostics Combined with Cancer Therapeutics Basics of combination of diagnostics with therapeutics are discussed ...

233 target leading to longer retention times and the ability to deliver a higher payload of the metal ion precisely to the targe ...

234 MenaINV rise and Mena11A fall the cancer cell transitions to a more metastatic shape and behavior. These metastasis promotin ...

235 treatment with Poteligeo to enable identifi cation of patients who would benefi t from the drug. Poteligeo Test IHC is for u ...

236 can interact with their surroundings. Interfering with the normal cell recognition phenomenon using a small or large sugar m ...

237 Table 10.3 Marketed anticancer personalized medicines Medicine/company Target Companion diagnostic (company) Indication Cetu ...

238 therapeutic monoclonal antibodies. Antigens can act as biochemical signatures or markers that distinguish a cancer cell from ...

239 ARH460-22-1 has cytotoxic activity in vitro against human breast cancer, colon cancer and melanoma cell lines. Ongoing rese ...

240 Personalized Cancer Vaccines There are several types of cancer vaccines, which include nucleic acid-based, MAb- based and ce ...

241 found that sipuleucel-T reduced the risk of death by 22.5 % compared with a placebo. The treatment extended the lives of pat ...

242 studies showed the safety of this approach, with side effects mainly limited to local reactions at the site of the vaccine i ...

243 with MyVax is safe and patients often mount tumor-specifi c immune responses (Timmerman et al. 2009 ). These results form th ...

244 2009 ). Following surgery to remove a part or whole of the tumor, the tissue specimen is shipped frozen to Agenus, which pre ...